Related Experiment Video

Updated: Mar 9, 2026

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
09:20

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

7.1K

The Three-Decade Long Journey in Heart Failure Drug Development

Kelly S Lewis1, Javed Butler2, Johann Bauersachs3

  • 1Department of Cardiology, Global Medical Affairs, Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ, USA. kelly.lewis@bayer.com.

Handbook of Experimental Pharmacology
|December 21, 2016
PubMed

Insights

Heart failure, a growing global health issue, affects both reduced and preserved ejection fraction types. Despite treatments for HFrEF, high mortality persists, and HFpEF lacks approved therapies, necessitating further research.

Area of Science:

  • Cardiology
  • Public Health
  • Clinical Medicine

Background:

  • Heart failure (HF) presents a significant global health challenge, exacerbated by an aging population and rising comorbidities.
  • Heart failure with reduced ejection fraction (HFrEF) has available treatments, yet morbidity and mortality rates remain high.
  • Heart failure with preserved ejection fraction (HFpEF) currently lacks approved therapeutic options, highlighting a critical unmet medical need.

Purpose of the Study:

  • To summarize the current burden of heart failure.
  • To review heart failure classification and definitions.
  • To discuss landmark clinical trials for both HFrEF and HFpEF.

Main Methods:

  • Literature review of epidemiological data.
  • Analysis of clinical trial outcomes.
  • Synthesis of current understanding of HF classification and treatment.

Main Results:

  • Heart failure is a progressive global disease with increasing prevalence.
  • Significant unmet needs exist for both HFrEF and HFpEF patient populations.
  • Existing therapies for HFrEF have not sufficiently reduced morbidity and mortality.

Conclusions:

  • Continued research and development are crucial to address the high morbidity and mortality associated with heart failure.
  • Novel therapeutic strategies are urgently required, particularly for HFpEF.
  • Addressing the unmet needs in HF requires a multifaceted approach including improved classification and treatment development.

Keywords:
HFpEFHFrEFHeart failureHeart failure statisticsHeart failure trials

More Related Videos

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine10:05

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

Published on: July 7, 2016

9.0K
A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs07:09

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs

Published on: February 18, 2022

2.4K

Related Concept Videos

Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
1.0K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.3K
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.7K
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
453
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
1.1K
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
509